Results 231 to 240 of about 811,687 (352)

Galectin‐3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE‐TIMI 58

ESC Heart Failure, EarlyView.
Abstract Background Galectin‐3 (Gal‐3) is a circulating biomarker of fibrosis, with higher levels being associated with an increased risk of progression of heart failure and kidney disease. Patients with type 2 diabetes mellitus (T2DM) are at increased risk of both.
Paul M. Haller, Stephen D. Wiviott, David D. Berg, Petr Jarolim, Erica L. Goodrich, Deepak L. Bhatt, Ingrid Gause‐Nilsson, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Itamar Raz, Marc S. Sabatine, David A. Morrow   +12 more
wiley   +1 more source

Correction: CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance. [PDF]

Front Endocrinol (Lausanne)
Contreras PH, Falhammar H.
europepmc   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

ESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann‐Kathrin Schäfer, Michael J. Koziolek, Manuel Wallbach   +9 more
wiley   +1 more source

Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study. [PDF]

Eur J Med Res
Hepşen S, Haymana C, Cavnar Helvacı B, Durantaş H, Toros B, Çakmak R, Güven M, Demirci İ, Keskin L, Kıyıcı S, Şahin Alak ZY, Sargın M, Tamer G, Balcı D, Aydoğan Bİ, Or Koca A, Aydemir M, Tarkun İ, Köksal P, Oğuz A, Demir Önal E, Baldane S, Kızılgül M, Çakal E, Çakır B, Polat ŞB, Yetkin İ, Bozkırlı E, Karaahmetli G, Fakı S, Yaghji NI, Öge A, Özbaş B, Topsakal Ş, Fırat SN, Bostan H, Karagün B, Bakıner OS, Kargılı Çarlıoğlu A, Evren B, Uğur K, Kılınç F, Batman A, Çakmak Demir S, Yazıcı D, Deyneli O, Arslan M, Topaloğlu O, Kocatepe K, Karagözoğlu K, Tekin S, Bayraktaroğlu T, Ertek Yalçın S, Kubat Üzüm A, Kocamaz GY, Şahin M, Aydın Y, Kutlu M, Sabuncu T, Cesur M, Yumuk VD, Bayram F, Sönmez A.   +62 more
europepmc   +1 more source

Studies on Reproductive Endocrinology in Non-human Primates: Application of Non-invasive Methods

, 2005
Keiko Shimizu
openalex   +2 more sources

Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop [PDF]

, 2008
Pinchas Cohen, Alan D. Rogol, Cheri Deal, Paul Saenger, Edward O. Reiter, Judith L. Ross, Steven D. Chernausek, Martin O. Savage, Jan M. Wit   +8 more
openalex   +1 more source

Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED‐AHF): A prospective, randomized, mechanistic study

European Journal of Heart Failure, EarlyView.
The impact of sodium chloride (NaCl) supplementation on proximal and distal tubular reabsorption in acute heart failure (AHF). Abstract Aims We questioned the long‐standing paradigm that sodium/chloride restriction is essential for effective decongestion in acute heart failure (AHF). This study compared the decongestive effects of two isotonic infusion
Jan Biegus, Gracjan Iwanek, Jeffrey Testani, Robert Zymliński, Marat Fudim, Mateusz Guzik, Piotr Gajewski, Piotr Ponikowski   +7 more
wiley   +1 more source

The use of thyroid hormones in the treatment of euthyroid patients with treatment-resistant depression. Data from a survey of 5695 European national endocrine professional organization members. [PDF]

Front Endocrinol (Lausanne)
Ludgate S, McGowan A, Moran C, Attanasio R, Žarković M, Nagy EV, Negro R, Papini E, Adler Cohen C, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin BN, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu MC, Ćirić J, Díez JJ, Dobnig H, Fadeyev V, Field BCT, Fliers E, Führer-Sakel D, Galofré JC, Hakala T, Jiskra J, Kopp PA, Krebs M, Kršek M, Kužma M, Lazúrová I, Leenhardt L, Luchytskiy V, Melo M, Metso S, Morgunova T, Niculescu DA, Perić B, Planck T, Poiana C, Marques Puga F, Robenshtok E, Rosselet P, Ruchala M, Riis KR, Shepelkevich A, Tronko MD, Frølich JS, Unuane D, Vardarli I, Visser WE, Vryonidou A, Younes YR, Yurenya E, Perros P, Hegedüs L.   +59 more
europepmc   +1 more source

Insights into tandem mass spectrometry for the laboratory endocrinology [PDF]

, 2013
Uberto Pagotto, Flaminia Fanelli, Renato Pasquali   +2 more
openalex   +1 more source

Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides

European Journal of Heart Failure, EarlyView.
Cancer patients presenting to the emergency department ED with dyspnoea. Among 2153 patients presenting to the ED with dyspnea, 473 (22.0%) had an active or past cancer. Acute heart failure (AHF) was the most common final diagnosis in both groups. Pneumonia and cancer‐related dyspnoea were more common in cancer patients.
Paolo Bima, Desirée Wussler, Pedro Lopez‐Ayala, Maria Belkin, Albina Nowak, Xueting Lin, Ivo Strebel, Fabiana Sgueglia, Eleni Michou, Androniki Papachristou, Laureve Chollet, Codruta Popescu, Nikola Kozhuharov, Samyut Shrestha, Gabriela Kuster, Katharina Rentsch, Arnold Von Eckardstein, Mascha Binder, Felix Mahfoud, Tobias Breidthardt, Christian Mueller   +20 more
wiley   +1 more source